We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




Latest Generation Coagulation Monitor Boasts Built-in WI-FI Connectivity

By LabMedica International staff writers
Posted on 13 Dec 2015
A new coagulation monitor for professional use combines two critical assays—the activated partial thromboplastin time (aPTT) test and the prothrombin time (PT) test—in a single small, portable instrument.

The medical equipment manufacturer Roche (Basel, Switzerland) recently announced the launch of the CoaguChek Pro II system in countries accepting the CE marking for diagnostic tools. More...
CoaguChek Pro II combines two tests in a single device for greater insight into patients’ coagulation status in acute care settings, such as emergency rooms, operating rooms, intensive care units, or anticoagulation clinics.

The instrument is small and portable, requiring only a small sample volume of eight microliters to run a full test, and accepts different blood sample types, including capillary blood from a finger prick as well as venous and arterial whole blood. Accuracy and precision of the test strips are guaranteed, since each lot of the test strips is precalibrated against the World Health Organization (WHO) reference method.

The instrument boasts built-in WI-FI connectivity, which allows test results to be transmitted automatically in real time to patients’ electronic health records, ensuring that vital information is immediately available at every point of care.

“Building on the best in class quality, CoaguChek Pro II is small, light, and convenient with accuracy and precision that our customers have come to expect from CoaguChek over the past 20 years,” said Jean-Claude Gottraux, head of professional diagnostics at Roche. “As the latest addition to the CoaguChek family, CoaguChek Pro II expands our coagulation point of care offering beyond self-monitoring and doctors’ offices to also include more specialized settings such as the ER and OR.”

Related Links:

Roche



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Online QC Software
Acusera 24•7
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Roche’s CE-Marked Elecsys pTau217 blood test is a single‑assay blood test measures phosphorylated tau 217, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease (image credit: Shutterstock)

Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection

Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more

Molecular Diagnostics

view channel
Image: Clarifying tumor microenvironment features and cancer-cell programs linked to treatment response could provide earlier insight into triple-negative breast cancer therapy (image credit: Shutterstock)

Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC

Triple-negative breast cancer (TNBC) is an aggressive subtype commonly treated with chemotherapy, yet outcomes vary widely among patients. Understanding the tumor features that drive this variability remains... Read more

Microbiology

view channel
Image: The initiative combines epidemiological and microbiological data with whole-genome sequencing to characterize circulating hospital lineages and resistance determinants (image credit: Shutterstock)

Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals

Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.